DHR · NYSE · Life Sciences Tools & Services
Life Sciences Tools & Services company based in Washington, D.C..
Last close, Oct 1, 2026
$211.76
Adjusted for splits and dividends
Last 12 months
-0.5%
S&P 500 +14.3% over the same dates
Market value
$149B
Last close × shares outstanding
Bets against the stock: 8.34M shares sold short (1.2% of shares outstanding), -13.4% vs the previous count, 2.7 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
3 sales
$12.7M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$24.6B
+2.9% vs the year before
Net income, fiscal 2025
$3.61B
As reported in the annual filing
Shares outstanding
703M
As of Jul 16, 2026
In fiscal 2025 the company spent $3.09B buying back its own shares and $878M on dividends. Cash actually paid, from its cash-flow statement.
Congress tradeSits on House Ways and Means, HealthHeld by the filer's joint per the disclosure. Disclosed 25 days after the transaction; reported as an official range, not an exact amount.
Congress tradeSits on House Ways and Means, HealthHeld by the filer's joint per the disclosure. Disclosed 23 days after the transaction; reported as an official range, not an exact amount.
Stock since the trade -3.2% · S&P 500 -0.2% · to Oct 1Traded 31 days after resultsStock 35% above its 52-week low and 10% below its high
47K → 7,755 shares held−83% of their stake
The boss of Danaher Corporation sold $8.57M of Danaher Corporation shares. Nobody planned it ahead of time.
Stock since the trade -3.2% · S&P 500 -0.2% · to Oct 1Traded 31 days after resultsStock 35% above its 52-week low and 10% below its high
58K → 47K shares held−19% of their stake
The boss of Danaher Corporation sold $2.46M of Danaher Corporation shares. Nobody planned it ahead of time.
Stock since the trade -3.2% · S&P 500 -0.2% · to Oct 1Traded 31 days after resultsStock 35% above its 52-week low and 10% below its high
7,755 → 0 shares held−100% of their stake
The boss of Danaher Corporation sold $1.7M of Danaher Corporation shares. Nobody planned it ahead of time.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Short sale volume: 39.4% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 41.0%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 6,700 shares (about $1.47M) were not delivered on time for settlement on Aug 24, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
13 approvals or clearances and 18 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
0 certified in FY2026 Q3, vs 1 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $212.88 on Oct 1, 2025 to $211.76 on Oct 1, 2026 (-0.5%). Disclosed trades in the last 12 months: 0 insider purchases, 20 insider sales, 2 Congress purchases, 4 Congress sales.
